News - Study On Breastfeeding
CCSI Commences Research Study on Breastfeeding Effectiveness with Kaiser Permanente, University of Colorado Health Sciences Center and Exempla St Joseph Hospital
NEW YORK and DENVER, Mar 30, 2000 /PRNewswire via COMTEX/ -- Chromatics Color Sciences International, Inc. (Nasdaq: CCSI) announced today that it has signed a Research Agreement with principal investigators from Kaiser Permanente, Kaiser Foundation HealthPlan of Colorado, the University of Colorado Health Sciences Center/The Children's Hospital and Exempla St. Joseph Hospital in Denver.
The investigators will study "The Relationship of Early and Frequent Breastfeeding to Peak Transcutaneous Bilirubin Levels" including observations of maternal use of CCSI's Colormate(R) TLc-BiliTest(R) transcutaneous bilirubin monitoring device. The study's purpose is to examine the effect of improved guidelines for breastfeeding mothers that may reduce the incidence of infant hyperbilirubinemia among breastfed infants, maximize breastfeeding effectiveness and decrease healthcare costs.
The goals of the study are to help determine optimal guidelines for initiation and frequency of breastfeedings, and to assess the use by mothers of CCSI's Colormate(R) TLc-BiliTest(R) System as a monitoring tool for jaundice in their infants. Although mother's breastmilk provides optimal infant nutrition, ineffective breastfeeding may lead to dehydration or elevated bilirubin levels in infants, called "exaggerated physiologic jaundice" or "breastfeeding jaundice". The researchers hope to produce sufficient data showing that if mothers follow improved guidelines while breastfeeding, then these concerns can be alleviated and the infants can safely receive the nutritional and immune system benefits of breastfeeding.
The study will include the use of the TLc-BiliTest(R) System by the mother to provide clinical data on use of the device in the home by a layperson/parent. The researchers specifically requested that the TLc-BiliTest(R) System be used for their study, and the Company has provided it for this trial after approval of the protocol by the IRB (Institutional Review Board).
The study will be led by Dr. Susan Niermeyer, Associate Professor of Pediatrics at the University of Colorado Health Sciences Center/The Children's Hospital in collaboration with Carol Grunfeld, MSN, RN, CPNP, Director of Pediatrics and OB/GYN Home Care Program, Kaiser Foundation Health Plan of Colorado, and Stefan Mokrohisky, MD, Department of Pediatrics, Kaiser Permanente Medical Group and Exempla St. Joseph Hospital in Denver.
Darby Macfarlane, the Chief Executive Officer of CCSI stated, "We're very gratified and proud that Dr. Niermeyer and Kaiser Permanente asked us to participate in this important study. To assist mother nature in resuming her
role and removing another obstacle from the natural and advantageous process between mother and child would indeed be an accomplishment. To do so while studying the potential for a whole new and significant market use for our product by mothers makes it even more exciting."
|
